Answers are grounded in this paper and cite their sources.
An epidemic illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), now named Coronavirus Disease 2019 (COVID-19), occurred in Wuhan, China. 1 The human-to-human contagious transmission of SARS-CoV-2 has been confirmed, leading to rapid spreading to tens of thousands of patients in China and other regions in the world.[2][3][4][5] Organ dysfunction, including acute respiratory distress syndrome (ARDS), shock, and death may occur.6 Therefore, many COVID-19 patients also suffered from anxiety, especially under treatment in intensive care units.However, due to currently very limited treatment options and no developed vaccines available for COVID-19, new treatment approaches are urgently needed.There were quite a few critical cases suffering from immune imbalance, 7 for which the efficacy of antiviral drugs might remain unsatisfactory or insufficient, especially in the later stages of disease progression.Thalidomide, referred to phocomelia, has been introduced as an anti-inflammatory therapy with remarkable efficacy in many autoimmune disorders, such as Abbreviations: ARDS, acute respiratory distress syndrome; IFN, interferon; IL, interleukin; MERS, Middle East respiratory syndrome; rRT-PCR, real-time reverse-transcriptase polymerase chain reaction; COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: